MedTrace Logo

Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome

NCT01890330 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-09-08

No results posted yet for this study

Summary

MetS is an early stage of CVD and is an appropriate target for dietary interventions. MetS is a clustering of risk factors (abdominal obesity, elevated serum triglycerides, low HDL-cholesterol, hypertension, elevated fasting blood glucose) accompanied by low grade chronic inflammation, hepatic steatosis (fatty liver) and reduced vascular function.

This study will investigate the effect of a 12 week intervention with canola oil versus the typical fat mixture in the Western diet on blood lipids, blood vessel function and MetS parameters. CVD risk will be assessed based on the profile of lipids and other factors in the blood as well using specialized equipment for non-invasive monitoring of blood vessel function.

Conditions

  • Metabolic Syndrome

Interventions

OTHER

Canola Oil 25 g/d

Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.

OTHER

Non-Canola Oil Mixture 25 g/d

Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.

Sponsors & Collaborators

  • Alberta Innovates Bio Solutions

    collaborator OTHER

  • Alberta Canola Producers Commission

    collaborator UNKNOWN

  • Canola Council of Canada

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Carla Taylor, PhD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890330 on ClinicalTrials.gov